Short Interest in Fresenius Medical Care AG (NYSE:FMS) Declines By 8.6%

Fresenius Medical Care AG (NYSE:FMS - Get Free Report) was the target of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 683,300 shares, a decline of 8.6% from the September 15th total of 747,500 shares. Based on an average daily volume of 304,500 shares, the days-to-cover ratio is currently 2.2 days.

Fresenius Medical Care Trading Up 0.0 %

Shares of FMS traded up $0.01 during mid-day trading on Thursday, reaching $20.04. The company's stock had a trading volume of 173,597 shares, compared to its average volume of 372,193. The stock has a market cap of $11.76 billion, a PE ratio of 22.52, a P/E/G ratio of 1.06 and a beta of 0.91. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. Fresenius Medical Care has a 52 week low of $16.37 and a 52 week high of $22.76. The company's fifty day moving average price is $19.92 and its two-hundred day moving average price is $20.05.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting analysts' consensus estimates of $0.38. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. The company had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.28 billion. On average, analysts predict that Fresenius Medical Care will post 1.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in Fresenius Medical Care by 21.8% during the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company's stock valued at $82,000 after buying an additional 758 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in Fresenius Medical Care during the 3rd quarter valued at $112,000. ORG Partners LLC purchased a new position in Fresenius Medical Care during the 1st quarter valued at $110,000. SageView Advisory Group LLC purchased a new position in Fresenius Medical Care during the 1st quarter valued at $127,000. Finally, Signaturefd LLC increased its position in Fresenius Medical Care by 8.4% during the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company's stock valued at $166,000 after purchasing an additional 672 shares during the period. 8.25% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

FMS has been the subject of several research analyst reports. StockNews.com initiated coverage on shares of Fresenius Medical Care in a research report on Tuesday, October 8th. They set a "strong-buy" rating for the company. Truist Financial boosted their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a "hold" rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $23.00.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.